(A) work closely with host governments, 
international partners, and other non-govern-
mental organizations to develop in-country in-
frastructure, personnel and other assets suffi-
cient to deliver vaccines where they are needed, 
when they are needed, and to administer the 
vaccines to appropriate target populations; 
(B) build on existing healthcare delivery 
infrastructure 
and 
relationships 
developed 
through the President’s Emergency Plan For 
AIDS Relief and other pre-existing, bilateral 
humanitarian aid programs between the United 
States and the target countries, as well as 
through pre-existing multilateral relationships 
and initiatives in target countries; 
(C) develop country operational plans tar-
geted primarily at lower- and middle-income 
countries without the infrastructure to manu-
facture, acquire, or administer vaccines on their 
own; 
(D) monitor how many people in such tar-
get countries received inoculations, the infection 
rate, and vaccine manufacture status, including 
as a result of the activities of the Program; and 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS
(E) monitor and prepare, on a daily basis, 
updates on the overall progress in non-targeted 
countries toward vaccinating their populations 
and ending the COVID–19 pandemic within 
their borders, to ensure that the Director re-
mains aware of overall global progress toward 
vaccinating the global population and ending 
the COVID–19 pandemic worldwide; and 
(3) following the end or abatement of the 
COVID–19 pandemic, the Program should shift to 
protect against future pandemics by coordinating a 
global disease surveillance network to identify and 
stop pathogens with pandemic potential before they 
spread uncontrollably by— 
(A) building on existing surveillance and 
prevention infrastructure and relationships de-
veloped through the National Security Council 
Directorate on Global Health Security and Bio-
defense as well as other pre-existing surveillance 
and prevention programs; 
(B) working with international partners to 
establish a coordinated disease surveillance sys-
tem, directly linked to decision-makers in for-
eign governments and non-governmental organi-
zations, such that certain agreed early-warning 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS
metrics would trigger timely and open commu-
nication 
between 
relevant 
decision-makers 
around the world; and 
(C) in addition to monitoring for early- 
warning signs of potential future pandemics, 
consider how to prevent or limit the potential 
for new spillover events by which new pathogens 
with pandemic potential are first transmitted to 
humans. 
(b) SENSE OF CONGRESS.—It is the sense of Con-
gress that— 
(1) the United States Government played a cru-
cial role in the unprecedented rapid development of 
the COVID–19 vaccines, substantially funding sev-
eral vaccine candidates and closely collaborating with 
Moderna on the NIH-Moderna vaccine; and 
(2) in the face of a global health emergency, the 
United States Government has broad authority, in-
cluding under the Defense Production Act (50 
U.S.C. 4501 et seq.) and chapter 18 of title 35, 
United States Code (commonly referred to as the 
‘‘Bayh-Dole Act’’), to ensure adequate supply of vac-
cines, necessary components, and raw materials 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS
through technology sharing and direct collaboration 
with manufacturers around the world. 
Æ 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6301
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS